A Phase 3 interventional study of DTG and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 125 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-07.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.
Drug: B/F/TAF · Drug: DTG Placebo · Drug: F/TAF Placebo
DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.
Drug: DTG · Drug: F/TAF · Drug: B/F/TAF Placebo
After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
Drug: B/F/TAF
After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
Drug: B/F/TAF
50 mg tablets administered orally, once daily
Also known as: Tivicay®
Drug pages: Emtricitabine · Tenofovir alafenamide
200/25 mg tablets administered orally, once daily
Also known as: Descovy®
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 milligrams (mg) FDC tablets administered orally, once daily
Also known as: GS-9883/F/TAF, Biktarvy®
Tablets administered orally, once daily
Tablets administered orally, once daily
Tablets administered orally, once daily
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 144
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 96
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 144
Change From Baseline in log10 HIV-1 RNA at Week 48
Time frame: Baseline, Week 48
Change From Baseline in log10 HIV-1 RNA at Week 96
Time frame: Baseline, Week 96
Change From Baseline in log10 HIV-1 RNA at Week 144
Time frame: Baseline, Week 144
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline, Week 48
Change From Baseline in CD4+ Cell Count at Week 96
Time frame: Baseline, Week 96
Change From Baseline in CD4+ Cell Count at Week 144
Time frame: Baseline, Week 144
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.
Time frame: Baseline, open-label Week 48
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.
Time frame: Baseline, open-label Week 48
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.
Time frame: Baseline, open-label Week 96
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.
Time frame: Baseline, open-label Week 96
Change From Baseline in CD4+ Cell Count at Week 48 Open-Label
Time frame: Baseline, open-label Week 48
Change From Baseline in CD4+ Cell Count at Week 96 Open-Label
Time frame: Baseline, open-label Week 96
Participants were enrolled at centers in Australia, Europe, North America, and the Dominican Republic. The first participant was screened on 11 November 2015. The last study visit occurred on 05 July 2021.
| Milestone | B/F/TAF | DTG + F/TAF | B/F/TAF to B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|---|---|
| Started | 327 | 330 | 0 | 0 |
| Completed | 266 | 277 | 0 | 0 |
| Not completed | 61 | 53 | 0 | 0 |
| Withdrew: Withdrew consent | 17 | 19 | 0 | 0 |
| Withdrew: Lost to follow-up | 19 | 16 | 0 | 0 |
| Withdrew: Randomized but never treated | 7 | 5 | 0 | 0 |
| Withdrew: Investigator's discretion | 7 | 2 | 0 | 0 |
| Withdrew: Death | 4 | 4 | 0 | 0 |
| Withdrew: Adverse event | 4 | 3 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 1 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 3 | 0 | 0 |
| Milestone | B/F/TAF | DTG + F/TAF | B/F/TAF to B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|---|---|
| Started | 0 | 0 | 254 | 265 |
| Completed | 0 | 0 | 225 | 235 |
| Not completed | 0 | 0 | 29 | 30 |
| Withdrew: Withdrew consent | 0 | 0 | 10 | 16 |
| Withdrew: Lost to follow-up | 0 | 0 | 14 | 6 |
| Withdrew: Death | 0 | 0 | 1 | 3 |
| Withdrew: Investigator's discretion | 0 | 0 | 2 | 2 |
| Withdrew: Non compliance with study drug | 0 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | 89.4 | 92.9 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm | 84.1 | 86.5 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm | 81.9 | 84.0 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm | 82.2 | 87.1 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm | 77.5 | 80.3 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm | 77.5 | 79.1 |
| log10 copies/mL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in log10 HIV-1 RNA at Week 48 | -3.07 ± 0.719 | -3.12 ± 0.672 |
| log10 copies/mL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in log10 HIV-1 RNA at Week 96 | -3.08 ± 0.703 | -3.10 ± 0.713 |
| log10 copies/mL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in log10 HIV-1 RNA at Week 144 | -3.06 ± 0.731 | -3.11 ± 0.672 |
| cells/μL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 180 ± 166.2 | 201 ± 165.9 |
| cells/μL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 96 | 237 ± 204.2 | 281 ± 209.3 |
| cells/μL | B/F/TAF | DTG + F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 144 | 278 ± 236.6 | 289 ± 218.5 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.
| percentage of participants | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm | 99.2 (97.1 to 99.9) | 99.6 (97.5 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.
| percentage of participants | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm | 75.3 (70.2 to 79.9) | 84.5 (79.6 to 88.7) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.
| percentage of participants | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm | 99.5 (97.5 to 100.0) | 99.1 (96.9 to 99.9) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.
| percentage of participants | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm | 68.1 (62.7 to 73.2) | 87.5 (83.0 to 91.3) |
| cells/μL | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 Open-Label | 304 ± 249.2 | 9 ± 198.0 |
| cells/µL | All B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 96 Open-Label | 336 ± 235.1 | -10 ± 181.1 |
Collected over Adverse Events: First dose date up to last dose date (maximum: 281.4 weeks) plus 30 days All-Cause Mortality: Randomization date through last visit/follow up date (maximum: 287.1 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF | 4/327 (1.2%) | 64/320 (20%) | 250/320 (78.1%) |
| DTG + F/TAF | 4/330 (1.2%) | 46/325 (14.2%) | 262/325 (80.6%) |
| B/F/TAF to B/F/TAF | 1/254 (0.4%) | 20/254 (7.9%) | 165/254 (65%) |
| DTG + F/TAF to B/F/TAF | 3/265 (1.1%) | 32/265 (12.1%) | 163/265 (61.5%) |
| Event | B/F/TAF | DTG + F/TAF | B/F/TAF to B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|---|---|
| CellulitisInfections and infestations | 6/320 | 1/325 | 1/254 | 2/265 |
| PneumoniaInfections and infestations | 1/320 | 4/325 | 2/254 | 2/265 |
| Anal abscessInfections and infestations | 3/320 | 0/325 | 0/254 | 0/265 |
| AppendicitisInfections and infestations | 3/320 | 2/325 | 0/254 | 1/265 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 3/320 | 0/325 | 0/254 | 0/265 |
| Acute kidney injuryRenal and urinary disorders | 3/320 | 2/325 | 0/254 | 0/265 |
| Covid-19Infections and infestations | 0/320 | 0/325 | 2/254 | 1/265 |
| Atrial fibrillationCardiac disorders | 1/320 | 1/325 | 0/254 | 2/265 |
| DeathGeneral disorders | 0/320 | 2/325 | 1/254 | 2/265 |
| AnaemiaBlood and lymphatic system disorders | 2/320 | 0/325 | 0/254 | 0/265 |
| Event | B/F/TAF | DTG + F/TAF | B/F/TAF to B/F/TAF | DTG + F/TAF to B/F/TAF |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 66/320 | 54/325 | 15/254 | 15/265 |
| NasopharyngitisInfections and infestations | 51/320 | 62/325 | 19/254 | 22/265 |
| HeadacheNervous system disorders | 57/320 | 59/325 | 16/254 | 19/265 |
| Upper respiratory tract infectionInfections and infestations | 44/320 | 54/325 | 15/254 | 17/265 |
| Back painMusculoskeletal and connective tissue disorders | 30/320 | 44/325 | 18/254 | 12/265 |
| NauseaGastrointestinal disorders | 31/320 | 43/325 | 8/254 | 11/265 |
| Covid-19Infections and infestations | 0/320 | 0/325 | 26/254 | 31/265 |
| FatigueGeneral disorders | 29/320 | 37/325 | 4/254 | 13/265 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 36/320 | 33/325 | 16/254 | 17/265 |
| SyphilisInfections and infestations | 34/320 | 33/325 | 20/254 | 17/265 |
Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of the study drug.
| Age, Continuous(years) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 37 ± 12.3 | 37 ± 11.6 | 37 ± 11.9 |
| Sex: Female, Male(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Female | 40 | 37 | 77 |
| Male | 280 | 288 | 568 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 7 | 10 | 17 |
| Black | 97 | 100 | 197 |
| Native Hawaiian or Pacific Islander | 1 | 0 | 1 |
| White | 183 | 195 | 378 |
| Other | 31 | 19 | 50 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 83 | 81 | 164 |
| Not Hispanic or Latino | 237 | 244 | 481 |
| Region of Enrollment(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Canada | 12 | 9 | 21 |
| Belgium | 4 | 4 | 8 |
| United States | 193 | 193 | 386 |
| Dominican Republic | 27 | 18 | 45 |
| Italy | 15 | 18 | 33 |
| United Kingdom | 21 | 23 | 44 |
| Australia | 4 | 10 | 14 |
| France | 7 | 5 | 12 |
| Germany | 20 | 28 | 48 |
| Spain | 17 | 17 | 34 |
| HIV-1 RNA(log10 copies/mL) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 4.39 ± 0.730 | 4.42 ± 0.669 | 4.41 ± 0.700 |
| HIV-1 RNA Categories(Participants) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| ≤ 100,000 copies/mL | 254 | 271 | 525 |
| > 100,000 ≤ 400,000 copies/mL | 54 | 41 | 95 |
| > 400,000 copies/mL | 12 | 13 | 25 |
| CD4 Cell Count(Cells/µL) | B/F/TAF | DTG + F/TAF | Total |
|---|---|---|---|
| Mean | 457 ± 255.3 | 454 ± 231.5 | 456 ± 243.4 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 125 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Nov 2015 to primary completion in May 2017, 18 months.
Results were first posted in Jun 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide · Bictegravir